Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Allergy & Immunology
•
Mast Cell Disorders
•
Primary Care
How do you discuss the overlap of POTS, Ehlers-Danlos and MCAS with patients?
Related Questions
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
How do you approach hypogammaglobulinemia in a patient with sarcoidosis?
How do you approach cardiovascular risk management in patients with rheumatic disease?
How often do you find a food allergy on a skin test in an EoE patient that when avoided will result in significant resolution of EoE?
How do you approach the management of a patient with RA on methotrexate who has gingivitis or or frequent cavities?
What is your approach for severe SCLE in patients unable to tolerate HCQ?
